Evidence review
Healing Peptides and the Gap Between Anecdote and Trial
BPC-157 and TB-500 have thirty years of animal work and a very thin human record. Here is exactly what is registered, what is published, and what neither shows.
What this page is doing
Not debunking. Counting.
The claim under examination is that certain peptides accelerate healing of tendon, muscle, gut or skin in humans. The way to evaluate it is to go to the trial registry and the published literature, state exactly what is there, and stop.
BPC-157: what the registry returns
A ClinicalTrials.gov search on the term "BPC-157" in August 2026 returned 3 studies. All three:
NCT02637284 — a phase 1 safety and pharmacokinetics record with a listed estimated enrollment of 42. Its listed status is "unknown", the registry's flag for a record whose sponsor has not verified it recently.
NCT07437547 — a phase 2 record in acute hamstring muscle strain, listed as recruiting, with an estimated enrollment of 120.
NCT07752381 — a study listed as not applicable, marked completed, with an actual enrollment of 40, evaluating a consumer product on inflammation markers.
That is the whole registry footprint on that query term on that date. A differently-worded query, or a trial registered elsewhere, would return a different set — this is a count of what that search returned, not a claim about every study ever conducted anywhere.
BPC-157: what a 2026 review concluded
A narrative review published in May 2026 searched PubMed/MEDLINE, Embase and the Cochrane Library from database inception to April 2026, plus patent databases and the websites of the FDA, EMA and WADA. Its stated finding: despite over three decades of preclinical research demonstrating consistent biological activity, pharmaceutical development remains rudimentary, with no approved formulation, no validated dosing regimen, and no completed phase 2 clinical trial1.
The same review reports a preclinical ADME study in two species confirming a plasma half-life under 30 minutes, linear dose-proportional kinetics, and intramuscular bioavailability of 14% to 51% depending on species — and describes the human pharmacokinetic profile as critically undercharacterised1.
Read that carefully, because it cuts both ways. "Consistent biological activity across three decades of preclinical work" is not nothing. Neither is "no completed phase 2". Both sentences are from the same paper. Our BPC-157 page carries the compound record.
TB-500 is not thymosin β4, and the difference is the whole story
This is the single most consequential confusion in the healing-peptide category.
Thymosin β4 is a 43-amino-acid protein. TB-500 is a short fragment of it — the registry record for the one trial using that name describes it as the "Thymosin Beta 4 17-23 Fragment"2.
Now the counts, both from ClinicalTrials.gov in August 2026. A search on "TB-500" returned 1 study: NCT07487363, a phase 1/2 record on cardiovascular biomarkers in stable atherosclerotic cardiovascular disease, listed as recruiting with an estimated enrollment of 80.
A search on "thymosin beta 4" returned 18 studies, including four records at phase 3 or phase 2/3 with listed enrollments of 601, 700, 317 and 70.
So a citation of "phase 3 trials of TB-500" is, in the set those two searches returned, a citation of trials of the parent molecule — mostly as an eye drop or a topical, for dry eye and wound healing, rather than as a systemic injection for tendon repair. The TB-500 page keeps the two separate.
What the thymosin β4 trials found
The phase 2 dry-eye trial most often quoted enrolled nine patients. Twelve eyes received the drops and six received vehicle. At day 56 the treated group showed a 35.1% reduction in ocular discomfort against vehicle (p = 0.0141) and a 59.1% reduction in total corneal fluorescein staining (p = 0.0108)3.
Nine patients. The paper itself opens its conclusion with "in this small trial"3.
The phase 3 that followed, NCT02974907, enrolled 601 participants and has posted results in the registry. On its two co-primary measures the posted values are 0.07 for the treatment arm against −0.04 for vehicle on ocular discomfort, and 0.07 against −0.01 on corneal fluorescein staining. The record posts no statistical comparison alongside those numbers, but the two arms are separated by less than 0.15 of a point on both scales.
A second phase 3 record, NCT03937882, lists an enrollment of 700 and is marked completed; the record retrieved in August 2026 carried no posted results.
For a sense of how young the systemic human record is even for the parent molecule: a first-in-human single- and multiple-dose phase 1 study of recombinant human thymosin β4 in healthy volunteers was published in 20214.
That sequence — striking result in nine patients, flat result in 601 — is the most compressed illustration of small-trial fragility in this whole category.
Why the anecdotes are so much more vivid than the data
Healing has a natural history. Most soft-tissue injuries improve on their own, over weeks, on a curve that is invisible from the inside.
An uncontrolled personal experience cannot separate the drug from the curve. That is not a failure of honesty on anyone's part; it is a structural limit of a sample size of one with no comparator and no blinding.
It is also why the phase 3 above matters more than the phase 2, and why the phase 2 mattered more than the case report before it.
What would change the picture
For BPC-157: a completed phase 2 with a published result. NCT07437547 is registered at phase 2 in acute hamstring strain with an estimated enrollment of 120 and was listed as recruiting in August 2026. If that reports, this page changes.
For TB-500 specifically, as opposed to the parent molecule: a trial that tests the fragment systemically against placebo on a healing endpoint. The one registered study on that term as of August 2026 measures cardiovascular biomarkers, not healing.
Until then, the honest summary is that the preclinical literature is large and the human literature is thin, and that those two facts are not in conflict — they describe different stages of drug development. Our page on why most peptide trials are small and short covers why the second one stays thin.
Frequently asked questions
Are there human trials of BPC-157?
A ClinicalTrials.gov search on the term "BPC-157" in August 2026 returned 3 studies: a phase 1 record with an estimated enrollment of 42 and a status of "unknown", a phase 2 record in acute hamstring strain listed as recruiting with an estimated 120, and a completed 40-participant study of a consumer product. A narrative review published in May 2026, searching to April 2026, reported no completed phase 2 clinical trial.
Is TB-500 the same as thymosin beta 4?
No. Thymosin β4 is a 43-amino-acid protein; TB-500 is a short fragment of it, described in its registry record as the thymosin beta 4 17-23 fragment. A search on "thymosin beta 4" returned 18 registered studies in August 2026 and a search on "TB-500" returned 1. Trials of the parent molecule are not trials of the fragment.
Did the thymosin beta 4 phase 3 trials work?
One of them, NCT02974907 with 601 participants, has posted results in the registry. Its two co-primary measures list 0.07 against −0.04 and 0.07 against −0.01 for treatment versus vehicle — a separation of less than 0.15 of a point on both scales, with no statistical comparison posted alongside. A second phase 3 record with a listed enrollment of 700 is marked completed and carried no posted results in August 2026.
Why do people report such strong results if the trials do not?
Most soft-tissue injuries improve on their own over weeks. An uncontrolled personal experience has no comparator, no blinding and a sample size of one, so it cannot separate the drug from the natural course of healing. That is a structural limit, not a question of anyone's honesty.
Does animal evidence count for nothing?
It counts as a reason to run a human trial. The 2026 review describes over three decades of preclinical research showing consistent biological activity for BPC-157, and in the same sentence reports no approved formulation, no validated dosing regimen and no completed phase 2. Both halves are true and they describe different stages of development.
References
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. https://pubmed.ncbi.nlm.nih.gov/42198317/
- ClinicalTrials.gov, U.S. National Library of Medicine (2026). NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD. ClinicalTrials.gov registry record. https://clinicaltrials.gov/study/NCT07487363
- Sosne G, Dunn SP, Kim C (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. https://pubmed.ncbi.nlm.nih.gov/25826322/
- Wang X, Liu L, Qi L, et al. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine. https://pubmed.ncbi.nlm.nih.gov/34346165/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.
Continue reading
Amylin Analogs: The Next Class After Incretins
An amylin analog has been FDA-approved since 2005. What changed is not the hormone — it is how long the molecule lasts. The trials, in order.
ReadCertificates of Analysis: What They Prove
A COA is a claim about a lot, not a guarantee about a vial. What each test answers, what a purity figure cannot say, and the gap the document never closes.
ReadCompounded Is Not the Trial Drug
A trial tests one defined article: a molecule, a form, a concentration, a container. Compounding changes some of those, and the evidence travels only that far.
Read503A vs 503B: What Is Actually in the Vial
One scheme is inspected against manufacturing standards; the other is not. What each may legally start from, and what the inspection record shows in practice.
ReadGrowth-Hormone Secretagogues: What the Evidence Actually Shows
These compounds reliably raise IGF-1. That is the surrogate. When trials measured function, fracture recovery or disease progression, the results changed.
ReadHow to Read a ClinicalTrials.gov Record
A registration is a filing, not a review. Fifteen fields, two real peptide records, and the specific places where a record quietly tells you it has stalled.
ReadIncretins Explained: GLP-1, GIP and Glucagon
Three hormones, three receptors, and a class of drugs built on them. What each one does, and why the receptor diagram predicts less than it looks like.
ReadMuscle During Rapid Weight Loss: What Has Been Measured
Roughly a quarter of the weight lost is lean mass — and that was true on placebo too. What the DXA substudies actually show, and how small they are.
ReadOpen-Label vs Blinded: What You Can Conclude
Masking is not a quality score — it decides which explanations a trial can rule out. Five real registry records, and the honest evidence on blinding itself.
ReadOral vs Injectable Peptides: What Changes
One molecule, two routes, one label — and roughly 73 times the milligrams per week. What the gut does to a peptide, and what it costs to get past it.
ReadHalf-Life and Dosing Frequency
From 1.5 minutes to a week, on labels for the same hormone family. Half-life is the number that decides whether a peptide is dosed before meals or once a month.
ReadReconstitution: The Arithmetic, Not the Advice
Concentration is mass divided by volume — except the naive division is wrong, and an FDA label's own numbers prove it. The maths, and what it cannot tell you.
ReadWhat a Phase 2 Result Does and Does Not Tell You
Phase 2 is a dose-finding experiment, not a verdict. Two peptide programmes where the phase 3 exists show exactly which parts of the number survive.
ReadRegistered but Never Reported: The Trials That Vanish
Completed trials that post no results are common and measurable. How to check a compound's registry file, and what the silence does and doesn't tell you.
ReadWhy n=30 Is Not the Same as n=3,000
Enrolment size is not a quality badge — it is precision, and it is the ability to see rare harm. Worked on real peptide trials, with the arithmetic shown.
ReadSurrogate Endpoints vs Outcomes That Matter
Most peptide claims rest on a marker moving, not on anything happening to a person. Two paired trials show what the difference costs to establish.
ReadWhy a Triple Agonist Is Not Simply Better Than a Dual
Adding a receptor adds a mechanism, a side-effect profile, and a reason a trial might read differently. The numbers do not rank the way the labels suggest.
ReadWhat a Peptide Is, and What the Word Hides
Three amino acids or sixty-three thousand daltons — both get called peptides. The definitional confusions that cause the most misreading, settled by labels.
ReadWhat “Research Chemical” Actually Means
The phrase is a sales category, not a regulatory one. What FDA has actually published about seventeen of these peptides, and what the label is doing instead.
ReadHow to Tell a Peptide Claim Is Outrunning Its Evidence
Twelve tells, each with a real case from the registry or the literature. Overstated peptide claims tend to fail on one of them, and usually the same one.
ReadWhat Happens When a Peptide Trial Fails
Four negative results, and what each one killed. A trial can fail an indication, a molecule, a surrogate, or nothing at all — and the difference matters.
ReadWho Funded the Trial, and Why It Matters
Sponsorship shifts conclusions more than it shifts methods. Where to find the funding line, what the Cochrane evidence measured, and what it did not.
ReadWhy Most Peptide Trials Are Small and Short
A registry census, August 2026: one compound has 759 registered studies, another has zero. The reasons are economic, not about whether the drug works.
Read